Patents by Inventor Ibon Gutierro Aduriz
Ibon Gutierro Aduriz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210169778Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: ApplicationFiled: February 10, 2021Publication date: June 10, 2021Applicant: Laboratorios Farmacéuticos ROVI, S.A.Inventors: GUILLERMO FRANCO RODRIGUEZ, IBON GUTIERRO ADURIZ
-
Publication number: 20210154302Abstract: An injectable depot composition suitable for forming an in situ intramuscular implant is provided. The composition includes sterile biodegradable thermoplastic polymer of polylactic acid (PLA), solvent for the PLA, and drug. After administration to a subject, a corresponding implant administers 0.1-2 milligrams of nonsteroidal aromatase inhibitor every day throughout a dosing period of about six months to about one year. The composition is used to treat subjects in need thereof.Type: ApplicationFiled: November 23, 2020Publication date: May 27, 2021Applicant: Laboratorios Farmacéuticos ROVI, S.A.Inventors: GUILLERMO FRANCO RODRIGUEZ, IBON GUTIERRO ADURIZ
-
Patent number: 11013683Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.Type: GrantFiled: June 3, 2019Date of Patent: May 25, 2021Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon Gutierro Aduriz, Guillermo Franco Rodriguez
-
Patent number: 11007139Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.Type: GrantFiled: June 28, 2019Date of Patent: May 18, 2021Assignee: Laboratorios Farmacéuticos ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Guillermo Franco Rodriguez
-
Publication number: 20210077380Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10933015Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: GrantFiled: March 6, 2019Date of Patent: March 2, 2021Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Patent number: 10912735Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: GrantFiled: August 19, 2019Date of Patent: February 9, 2021Assignee: Laboratorios Farmacéuticos ROVI, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Patent number: 10881605Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: January 22, 2019Date of Patent: January 5, 2021Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 10809212Abstract: A nuclear magnetic resonance method of analysis for glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method allows for their identification and for relative quantification of respective characteristic signals by 1H-NMR and/or 1H-13C HSQC.Type: GrantFiled: March 20, 2020Date of Patent: October 20, 2020Assignee: LABORATORIOS FARMACÉUTICOS ROVI, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Publication number: 20200271601Abstract: A nuclear magnetic resonance method of analysis for glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method allows for their identification and for relative quantification of respective characteristic signals by 1H-NMR and/or 1H-13C HSQC.Type: ApplicationFiled: March 20, 2020Publication date: August 27, 2020Applicant: LABORATORIOS FARMACÉUTICOS ROVI, S.A.Inventors: Guillermo FRANCO RODRIGUEZ, Ibon GUTIERRO ADURIZ
-
Patent number: 10705037Abstract: An analytical method employing nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method is used for identification and the relative quantification of characteristic signals by 1H-NMR and/or 1H-13C HSQC.Type: GrantFiled: January 18, 2019Date of Patent: July 7, 2020Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Publication number: 20200085728Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: October 17, 2019Publication date: March 19, 2020Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20200024013Abstract: A system for and method of gravimetric filling of a solid product in sterile conditions in a pharmaceutical container of small dimensions including syringes, vials, capsules, ampoules, single-dose devices, inhalers, bottles, carpules, well(s) of blister pack(s), sachets or bags with solid substances selected from the group formed by powder, lyophilizate, granules, pellets, nanoparticles or microparticles. More particularly, it relates to a process for the gravimetric filling of pharmaceutical containers with one or more sterile solid pharmaceutical substances or sterile excipients dosed and prepared in an aseptic environment.Type: ApplicationFiled: September 27, 2019Publication date: January 23, 2020Applicant: LABORATORIOS FARMACÉUTICOS ROVI, S.A.Inventors: ELENA CEBADERA MIRANDA, IBON GUTIERRO ADURIZ, MARIA GARCIA AMO
-
Publication number: 20190365643Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: ApplicationFiled: August 19, 2019Publication date: December 5, 2019Applicant: Laboratorios Farmacéuticos ROVI, S.A.Inventors: GUILLERMO FRANCO RODRIGUEZ, IBON GUTIERRO ADURIZ
-
Patent number: 10463607Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: December 14, 2018Date of Patent: November 5, 2019Assignee: LABORATORIOS FARMACEUTICS ROFI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20190328654Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.Type: ApplicationFiled: June 3, 2019Publication date: October 31, 2019Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRIGUEZ
-
Publication number: 20190321286Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.Type: ApplicationFiled: June 28, 2019Publication date: October 24, 2019Applicant: Laboratorios Farmacéuticos ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRIGUEZ
-
Publication number: 20190254960Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.Type: ApplicationFiled: March 28, 2019Publication date: August 22, 2019Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRIGUEZ
-
Publication number: 20190231682Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: ApplicationFiled: March 6, 2019Publication date: August 1, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: GUILLERMO FRANCO RODRIGUEZ, IBON GUTIERRO ADURIZ
-
Patent number: 10350159Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.Type: GrantFiled: November 26, 2014Date of Patent: July 16, 2019Assignee: Laboratories Farmacéuticos Rovi, S.A.Inventors: Ibon Gutierro Aduriz, Guillermo Franco Rodríguez